Assessment of functioning in patients with schizophrenia and schizoaffective disorder with the Mini-ICF-APP: a validation study in Italy by unknown
Pinna et al. Int J Ment Health Syst  (2015) 9:37 
DOI 10.1186/s13033-015-0030-x
RESEARCH
Assessment of functioning in patients 
with schizophrenia and schizoaffective disorder 
with the Mini-ICF-APP: a validation study in Italy
Federica Pinna1, Andrea Fiorillo2, Massimo Tusconi1, Beatrice Guiso1 and Bernardo Carpiniello1*
Abstract 
Background: The aim of the study was to evaluate validity of the Italian Mini-ICF-APP (Mini-ICF Rating for Limitations 
of Activities and Participation in Psychological Disorders) in schizophrenia and related disorders.
Methods: 74 outpatients affected by schizophrenia or schizoaffective disorders attending a University-based com-
munity mental health centre were recruited to the study. All participants underwent comprehensive evaluation using 
standardized instruments to assess clinical, neurocognitive and functional status. Concurrent validity of Mini-ICF-APP 
was evaluated and compared to severity scores obtained using the Clinical Global Impression-Schizophrenia scale 
(CGI-SCH), Positive and Negative Syndrome scale (PANSS), Mini Mental State Examination test (MMSE), Brief Assess-
ment of Cognition in Schizophrenia scale (BACS) and Personal and Social Performance scale (PSP). Construct valid-
ity was evaluated by comparing scores obtained at Mini-ICF-APP by remitted versus non-remitted patients, and by 
recovered versus unrecovered patients. Discriminant validity was evaluated comparing scores on Mini-ICF-APP and 
Subjective Well-being (SWN) scale. Results: the total score and 12 out of the 13 Mini-ICF-APP items correlated sig-
nificantly with total score at PSP; Mini-ICF-App total score was moreover significantly correlated with total scores at 
CGI-SCH, PANSS, MMSE, as well as with several BACS items. Total scores obtained at Mini-ICF-APP were significantly 
higher among remitted and recovered patients. No relevant correlations were found between scores of Mini-ICF-APP 
and SWN scales.
Results: The total score and 12 out of the 13 Mini-ICF-APP items correlated significantly with total score at PSP; Mini-
ICF-App total score was moreover significantly correlated with total scores at CGI-SCH, PANSS, MMSE, as well as with 
several BACS items. Total scores obtained at Mini-ICF-APP were significantly higher among remitted and recovered 
patients. No relevant correlations were found between scores of Mini-ICF-APP and SWN scales.
Conclusion: the Italian version of Mini-ICF-APP is a valid instrument for use in evaluating functioning in chronic 
patients with schizophrenia and related disorders.
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Background
Among all mental disorders, schizophrenia is undoubtedly 
the most frequently related to the development of disabil-
ity [1]. Indeed, approx. 80 % of adults affected by schizo-
phrenia and related disorders have been estimated to show 
persistent deficits in personal and social functioning [2]. 
Although clinical remission [3] is seen as the main goal 
of treatment, nowadays recovery, which implies a satis-
factory level of functioning [4], is viewed as the ultimate 
target. Thus, the importance of personal and social func-
tioning is of course indisputable, also bearing in mind that 
functioning deficits are comprised among the basic diag-
nostic criteria for schizophrenia and other mental disor-
ders. However, in clinical practice the routine assessment 
of functioning is still uncommon for a series of reasons, 
likely including the lack of a simple, user-friendly rating 
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scale for use as a reference tool; however, on the interna-
tional scenario [5] a series of reliable and valid instruments 
such as GAF [6], SOFAS [7], PSP [8], and WHO-DAS2 [9] 
are available. In this context, the Mini-ICF-APP, specifi-
cally designed in line with parameters of the World Health 
Organization International Classification of Functioning, 
Disability and Health (ICF) for use in mental health set-
tings, was first developed and validated in Germany [10, 
11] and recently translated and validated in English [12] 
and Italian [13]. The original German version was vali-
dated on a sample of patients affected by non-psychotic 
mental disorders, whilst both the English and Italian ver-
sions were validated using mixed patient samples, includ-
ing a limited number of subjects with schizophrenia or 
other psychotic disorders. Accordingly, the present study 
was designed with the aim of validating the instrument for 
use in schizophrenia and schizoaffective disorders, in the 
context of an ongoing observational, prospective study on 
remission and recovery in chronic psychotic patients [14].
Methods
Sample
This cross-sectional study was conducted on a con-
venience sample of the first 74 outpatients affected by 
schizophrenia or schizoaffective disorders according 
to DSM-IV-TR, who attended a University-based com-
munity mental health centre (CMHC) and had previ-
ously concluded a two-year follow up period in the above 
cited observational study [14]. Patients with comorbid 
psychiatric and/or physical disorders were included in 
the study, with the exception of those affected by men-
tal retardation or severe organic brain diseases. Subjects 
underwent standard care routinely available in Ital-
ian CMHCs (clinical monitoring at least on a monthly 
basis; pharmacological treatment; home care when 
required, psychosocial and rehabilitation interventions 
tailored to patient’s needs). The study was approved by 
the Ethics Committee of the Local Health Authorities in 
Cagliari (Italy) and was conducted in compliance with 
national laws. All patients gave their informed consent 
to take part in the study. The sample included patients 
affected by schizophrenia (N  =  32, 43  %) or schizoaf-
fective disorders (N = 42, 57 %). The sociodemographic 
characteristics of the sample are reported in Table 1; clin-
ical characteristics are reported in Table  2. The sample 
included patients who were mostly male (70  %), with a 
mean age of 43.5 years, single (85 %), unemployed (77 %), 
and with a good level of education (mean years of edu-
cation = 11). Patients were characterized by early age at 
onset of the illness (approx. 23 years), a long clinical his-
tory (mean duration approx. 15 years), and a continuous 
course of the disorder (approx. 57 % of cases); all patients 
had been prescribed psychopharmacological treatment.
Ratings
Evaluation was performed by residents in psychia-
try using a set of standardized methods, after adequate 
training in the use of all adopted instruments. Personal 
and social data, and clinical history were collected in a 
structured interview purpose-developed for the study. 
After providing informed consent, patients were inter-
viewed using the Italian versions [15, 16] of SCID-I [17] 
and SCID-II [18]; inter-rater reliability, assessed using 
Cohen’s K before the study, was higher than 0.80. Symp-
tom severity was evaluated using the Italian version [19] 
of PANSS [20], consisting of 30 items grouped into three 
distinct symptom clusters (positive, negative, general psy-
chopathology) rated on a 7 point scale; an accurate pic-
ture of symptomatology is generally based on summary 
score obtained for each symptom cluster and on total 
score. Interviews were conducted by means of the Ital-
ian version [21] of the Structured Clinical Interview for 
Positive and Negative Scale (SCI-PANSS) [22]. Ratings 
were based on criteria indicated in the PANSS Manual 
[23] and, wherever possible, PANSS assessment included 
a standard section of queries addressed to treating clini-
cians and caregivers. The global clinical status was also 
evaluated by CGI-SCH [24], the version of the CGI (clini-
cal global impression scale) adapted for use in Schizo-
phrenia; the CGI-SCH provides for the global assessment 
of positive, negative, cognitive, and depressive symptoms 
and overall clinical condition over the week before the 
visit; CGI takes three aspects into account: severity of 
symptoms, global improvement and an efficacy index. For 
the purposes of this study, only the severity scale (CGI-
SCHs) was used; scores ranged from 1 (no symptoms) 




 Males 52 (70.3)
 Females 22 (29.7)
Age
 Mean ± SD 43.46 (10.06)
 Range 25–68
Education
 Mean years ± SD 10.67 (3.88)
 Range 4–14
Marital status N (%)
 Singles 63 (85.1)
 Married 11 (14.9)
Occupation N (%)
 Employed 17 (23)
 Unemployed 57 (77)
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to 7 (most severe symptoms). Cognitive functioning was 
evaluated by means of BACS [25], a scale comprising a 
series of cognitive dimensions, namely list learning, digit 
sequencing, category instances and controlled oral word 
association test, symbol coding and executive functions; 
a gender/age/education adjusted score, and subsequently 
an equivalent score were calculated [26]. MMSE [27] was 
also administered, calculating an age/education adjusted 
score [28]. Functioning was evaluated by PSP [8], 
assumed as a gold standard, to assess social functioning 
of patients in four main areas: socially useful activities, 
personal and social relationships, self-care and disturb-
ing/aggressive behaviours. Each area was evaluated on a 
six-point scale, where lower ratings indicate better func-
tioning. A comprehensive overall score ranging from 1 
(maximum dysfunction) to 100 (maximum functioning) 
was attributed, based on scores obtained at each single 
area. A total score exceeding 70 indicates a condition 
of “functional remission”, with scores related to overall 
good functioning. A non-standardized interview was 
conducted with the patient, caregivers (when available) 
and with the treating physician, with the aim to assess 
functioning by means of PSP. Patients were also submit-
ted to the Subjective Well-being under Neuroleptic scale 
(SWN-S) [29], a self-administered rating scale devoted to 
evaluating the psychological and physical well-being of 
patients treated with neuroleptics. For the purpose of the 
study the short version (20 items, including 5 subscales: 
mental functions, self-control, physical function, emo-
tional control, social capability) was used. The Mini-ICF-
APP [10, 11] is a clinician-rated instrument developed 
to measure limitations of capacity in people with mental 
disorders; these limitations are rated in terms of compe-
tence throughout thirteen domains, namely adherence to 
regulations, planning and structuring of tasks, flexibility, 
competency, endurance, assertiveness, contact with oth-
ers, group integration, intimate relationships, non-work 
activities, self-care, mobility and competence to judge 
and decide. Each dimension is rated on a five-point Likert 
scale (0 =  no impairment; 5 =  total disability). Ratings 
are based on information provided by patients, carers, 
clinical records, as well as direct observation of subjects 
and on anchor definitions of each item described in the 
Italian version of the Manual [30].
Inter-rater reliability of PANSS evaluations in terms 
of ICC (Intraclass correlation coefficient) ranged from 
0.65–0.95 for the PANSS total score, from 0.72–0.97 or 
the CGI-SGH total score, from 0.79–0.94 for the PSP 
total score and from 0.81–0.93 for Mini-ICF-APP total 
score.
Validity
Concurrent validity was evaluated calculating the correla-
tions between scores at Mini-ICF-APP and PSP, the latter 
being considered the standard of reference for evaluation 
of personal and social functioning; moreover, correla-
tions of scores obtained at Mini-ICF-APP and PANSS, 
CGI-SCHs, BACS, MMSE were calculated, based on the 
hypothesis of an existing, significant correlation between 
results relating to symptoms and cognitive status and 
Table 2 Clinical characteristics of the sample
Characteristics Statistics
Diagnosis N (%)
 Schizophrenia 32 (43.2)
 Schizoaffective disorders 42 (56.8)
Age at onset
 Mean ± SD 22.83 (10.06)
 Range 13–53
Duration of untreated psychosis
 Mean months ± SD 26.05 (53.85)
 Range 24–564
Comorbidities N (%)
 Anxiety disorders 7 (9.5)
 Personality disorders 8 (11.0)
 Alcohol abuse/dep 9 (12.3)
 Other subst abuse/dep 16 (21.9)
Previous clinical course N (%)
 Episodic with remission 11 (14.9)
 Episodic without remission 17 (23.0)
 Continuous 42 (56.8)
 Non specified 4 (5.4)
Previous hospital adm N (%)
 Yes 47 (63.5)
 No 27 (36.5)
Previous suicide attempts N (%)
 Yes 20 (27)
 No 54 (73)
Previous legal problems N (%)
 Yes 6 (8.1)
 No 68 (91.9)
Treatments N (%)
 Antipsychotics 74 (100.0)
 Mood stabilizers 17 (23.0)
 Antidepressants 19 (25.7)
 Anxiolytics 42 (56.7)
 Other 13 (17.6)
 Psychotherapy 9 (12.1)
 Rehabilitation programmes 16 (21.6)
Remission N (%)
 Clinical 40 (54.1)
 Functional 22 (29.7)
 Clinical + functional (recovery) 20 (27.0)
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functioning (i.e. the lower the scores obtained at clini-
cal and cognitive scales, the lower the score at Mini-
ICF-APP). Construct validity was evaluated by means of 
known-groups technique, which involves administering 
the measurement instrument to groups expected to dif-
fer due to known characteristics. Thus Mini-ICF-APP 
was evaluated by comparing differences in mean scores 
at each single item and total score obtained by “remitted” 
and “non remitted” patients and “recovered” and “unre-
covered” subjects at the time of evaluation (24 months). 
The working hypothesis was based on the assumption 
that both remission and recovery should be associated 
with achievement of better results at Mini-ICF-APP, 
i.e. lower mean scores. Clinical remission was assessed 
using the schizophrenia remission working group crite-
ria (SRWG-cr) [30], based on ratings at eight focal symp-
toms in positive, negative and general psychopathology 
subscales of PANSS (P1, P2, P3, N1, N4, N6, G5, G9); 
patients were judged to be in clinical remission accord-
ing to a severity criterion (scores obtained at each of 
these items were required to be ≤3 points, indicating 
mild severity of symptoms). Due to the cross-sectional 
nature of the study, clinical remission was evaluated on 
the basis of severity criterion alone, excluding the dura-
tion criterion (remission maintained for 6-months). With 
regard to functional remission, patients with a PSP total 
score >70, i.e. cut-off score indicating subjects devoid of 
significantly impaired functioning [8], were deemed to be 
remitted. Patients’ overall clinical status was taken into 
account, and assessments were carried out to determine 
whether or not they could be considered as “recovered”; 
for this purpose, due to the lack of a univocal definition 
for recovery [31, 32], patients characterized by both clini-
cal and functional remission were taken as being recov-
ered. Discriminant validity was evaluated calculating the 
correlations between scores at Mini-ICF-APP and SWN-
S, a scale specifically devoted to evaluate subjective-well 
being of patients undergoing antipsychotic treatment, on 
the basis of the hypothesis that no significant correlation 
should be found between results relating to functioning 
and treatment-related well-being measures.
Statistical analysis
Categorical data were analyzed using Pearson’s χ2 test 
or Fisher’s exact test; continuous variables were assessed 
by means of Student’s “t” test for independent samples. 
The magnitude of differences in mean scores obtained at 
different rating scales used in the study was calculated 
by means of Cohen’s “d”. Correlations between continu-
ous variables were calculated the Pearson’ r coefficient. 
Data analyses were performed using SPSS 19.0. Level 
of significance was set at a p value ≤0.05 for two-tailed 
hypothesis.
Results
Ratings at PANSS, CGI-SCHs, BACS, MMSE and PSP are 
reported in Table 3. Mean scores obtained at clinical and 
cognitive scales show low-moderate levels of severity and 
impairment, as expected in a cohort of relatively stable 
patients in a community treatment setting. No significant 
gender or diagnosis differences were detected for soci-
odemographic and clinical variables. The median score 
at Mini-ICF-APP is generally comprised between 1 and 
2 for the majority of items, thus indicating a low-mod-
erate level of impairment (Table  4); no differences were 
found in mean scores according to gender and diagnosis. 
With regard to correlational analyses, Mini-ICG-APP 
total score displayed a significant correlation with PSP 
total score and scores at the PSP subscales “socially use-
ful activities”, “personal and social relationship” and “self-
care”; all Mini-ICF-APP items correlated significantly 
with PSP total score, with the exception of the “Mobil-
ity” item; 4 out of 13 items of Mini-ICF-APP (Adherence 
to regulations, Structuring of tasks, Flexibility, Self-Care) 
featured a significant correlation with scores obtained 
at the PSP subscales “socially useful activities”, “personal 
and social relationship” and “self-care”, while 8 out of 
13 items of Mini-ICF-APP (Competency, Endurance, 
Assertiveness, Contact with Others, Group Integration, 
Intimate Relations, Spontaneous activity, Judgement) 
correlated significantly with 2 out of 4 PSP subscales, 
namely “Socially Useful Activities”, “Personal and Social 
Relationship”; only one Mini-ICF-APP item (mobil-
ity) was devoid of any correlation with PSP subscales 
(Table 5). In the symptomatology domain, Mini-ICF-APP 
total score significantly correlated with scores at CGI-
SCHs cognitive and depressive subscales and with the 
overall scale; moreover, a correlation was observed with 
PANSS total score and negative and general psychopa-
thology scales (Table 6). With regard to cognition, Mini-
ICF-APP total score significantly correlated with MMSE 
score, and with scores at BACS scales “Verbal memory”, 
“Verbal fluency” and “Tower of London” (Table 7).
On assessing construct validity, total mean scores 
of clinically remitted patients on Mini-ICF-APP were 
found to be significantly higher than those of unremitted 
patients; moreover, clinically remitted patients obtained 
significantly higher mean scores at 10 out of 13 Mini-
ICF-APP items (Table  8). Similarly, total mean scores 
obtained by functionally remitted subjects at Mini-ICF-
APP were significantly higher than those of unremitted 
patients, with significantly higher mean scores being 
attained in 9 out of 13 items compared to functionally 
unremitted patients (Table  9). Mean total Mini-ICF-
APP scores rated by recovered patients were significantly 
higher than those of unrecovered subjects, with similar 
results being registered in 4 out of 13 items of the scale 
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(Table 10). Finally, no significant correlations were found 
between scores at Mini-ICF-APP and SWN-S scales 
with the only exception of the ICF “persistence” scale, 
showing a significant negative correlation with SWN-S 
Self-control (r = −0.361, p < 0.01), Physical Functioning 
scales (r = −0.301, p < 0.01) and with SWN-total score 
(r = −0.305, p < 0.01).
Discussion
The patient sample studied provided an adequate rep-
resentation of chronic patients with schizophrenia and 
related disorders generally attending community mental 
health centres in Italy. Indeed, the sample was made up 
prevalently by middle-aged, single, unemployed, fairly 
well educated males, with a long duration of illness, early 
age at onset, and continuous course of the disorder; rat-
ings obtained at CGI-SCH, PANSS, MMSE, BACS and 
MMSE, relating to symptoms, cognition and functioning, 
denote a fairly stable clinical condition characterized by a 
low/moderate symptoms’ severity, cognitive impairment 
and social disability, as expected in a cohort of relatively 
stable, chronic patients in a community setting. Indeed, 
approximately 50 % of our patients were in clinical remis-
sion, slightly less than one-third in functional remission, 
and about one quarter viewed as recovered in line with 
the adopted criteria, a finding largely consistent with 
previous data published by our group [14, 33] and with 
literature findings [34–37]. Mean and median scores 
obtained at Mini-ICF-APP were generally comprised 
between 1 and 2 for the majority of items, thus indicating 
Table 3 Rating scales mean scores
CGI-SCHs clinical global impression schizophrenia severity; PANSS positive and negative symptoms scale; BACS brief assessment cognition scale; MMSE mini mental 
state examination; PSP personal and social performance scale
Rating scale Mean value (SD) Median Range
CGI SCHs positive symptoms 2.27 (1.43) 2.00 1–6
CGI SCHs negative symptoms 2.78 (1.40) 3.00 1–6
CGI SCHs depressive symptoms 2.20 (1.08) 2.00 1–6
CGI SCHs cognitive symptoms 2.69 (1.43) 3.00 1–7
CGI SCHs total score 3.12 (1.22) 3.00 1–6
PANSS positive 10.36 (3.60) 9.00 7–25
PANSS negative 14.51 (6.93) 12.50 7–36
PANSS general psychopathology 26.51 (8.84) 23.00 16–47
PANSS total score 51.39 (17.0) 47.00 30–91
MMSE 26.04 (3.90) 27.00 11–30
BACS list learning 14.57 (11.80) 11.57 2.75–53.25
BACS digit sequencing task 11.26 (5.88) 11.17 0.25–28.25
BACS verbal fluency/category istances 10.87 (5.24) 10.00 1.00–23.25
BACS semantic fluency/controlled oral word test 15.38 (5.65) 14.50 1.00–34.25
BACS symbol coding 26.13 (13.57) 23.25 0.75–65.75
BACS tower of London 9.36 (7.15) 6.25 0–22.50
PSP socially useful activities 2.54 (1.32) 3.00 0–5
PSP person soc relat 2.39 (1.22) 2.00 0–5
PSP selfcare 0.81 (1.1) 0.00 0–4
PSP dist aggress behav 0.39 (0.79) 0.00 0–3
PSP total 55.65 (16.24) 60.00 18–90
Table 4 Mini-ICF-APP mean/median scores
Item Mean value (SD) Median Range
Adherence to regulations 0.89 (1.07) 1.00 0–4
Structuring of tasks 1.57 (1.23) 1.00 0–4
Flexibility 1.99 (1.14) 2.00 0–4
Competency 2.01 (1.20) 2.00 0–4
Endurance 1.89 (1.34) 2.00 0–4
Assertiveness 1.50 (1.21) 1.00 0–4
Contact with others 1.62 (1.22) 1.50 0–4
Group integration 1.62 (1.27) 2.00 0–4
Intimate relations 1.89 (1.25) 2.00 0–4
Spontaneous activity 1.78 (1.17) 2.00 0–4
Self-care 0.70 (0.84) 0.50 0–3
Mobility 0.85 (1.15) 0.00 0–4
Judgement 1.74 (1.12) 2.00 0–4
Total score 20.07 (11.77) 18.50 0–46
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a low-moderate level of impairment, with only two items 
(self-care and mobility) showing very low scores (both 
means and medians lower than one), indicating the 
absence of, or minimal impairments in these areas; this 
finding was very similar to that of Balestrieri et al. in their 
validation study of the Italian version of the Mini-ICF-
APP [13]. In our sample, Mini-ICF-APP mean total score 
was approx. 20, somewhat lower than that observed in the 
subsample of schizophrenic subjects (mean score approx. 
30) in the above cited study [13], and higher than that 
observed by Molodynski et al. [12] (mean score approx. 
14) in a subsample of schizophrenic patients included in 
the validation study for the English version of the instru-
ment. Bearing in mind that our sample was constituted 
by a cohort of clinically chronic outpatients who were all 
on antipsychotic treatment, the somewhat low level of 
disability reflected by the mean total score at Mini-ICF-
APP is not surprising, and is consistent with the English 
study, which similarly comprised schizophrenic outpa-
tients in attending two community mental health centres, 
featuring a low-moderate level of severity of symptoma-
tology and functioning, as reflected respectively by mean 
scores at BPRS (approx. 38) and PSP (approx. 53). On 
the contrary, the study conducted by Balestrieri et  al. 
Table 5 Correlations between Mini-ICF-APP and PSP scores
* p < 0.05, ** p < 0.01
PSP socially  
useful activities
PSP personal  
and social relationships
PSP selfcare PSP aggressive and  
disturbing behaviours
PSP total score
Mini ICF adherence to 
regulations
0.342** 0.305** 0.303** 0.181 −0.426**
Mini ICF structuring of tasks 0.305** 0.414** 0.268* 0.205 −0.389**
Mini ICF flexibility 0.367** 0.406** 0.242* 0.112 −0.383**
Mini ICF competency 0.460** 0.360** 0.182 0.038 −0.452**
Mini ICF judgement 0.352** 0.393** 0.117 0.146 −0.355**
Mini ICF endurance 0.496** 0.385** 0.109 0.105 −0.459**
Mini ICF assertiveness 0.402** 0.403** 0.157 0.036 −0.376**
Mini ICF contact with others 0.339** 0.447** 0.162 0.141 −0.394**
Mini ICF group integration 0.433** 0.423** 0.147 0.123 −0.417**
Mini ICF intimate relations 0.368** 0.459** 0.178 0.169 −0.481**
Mini ICF spontaneous 
activity
0.331** 0.384** 0.183 0.196 −0.474**
Mini ICF self-care 0.417** 0.408** 0.314** 0.137 −0.465**
Mini ICF mobility 0.152 0.139 0.120 −0.055 −0.163
Mini ICF total score 0.475** 0.491** 0.241* 0.152 −0.520**
Table 6 Correlations between Mini-ICF-APP total score, CGI-SCH and PANSS ratings





























0.062 0.305** 0.325** 0.248* 0.455** 0.189 0.389** 0.276* 0.342**
Table 7 Correlations between Mini-ICF-APP total scores, MMSE and BACS
* p < 0.05, ** p < 0.01
MMSE BACS list  
learning
BACS digit  
sequencing  
task
BACS verbal  
fluency/category 
instances
BACS semantic  
fluency/controlled  
oral word test
BACS symbol  
coding
BACS ower  
of London
−0.260* −0.237* 0.215 −0.390** −0.225 −0.146 −0.277*
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[13] included a subsample of schizophrenic patients in 
the care of a CMHC who were characterized by a more 
severe clinical status (median CGIs  =  6; BPRS median 
score 75), and of which 40  % were not taking any form 
of psychopharmacological treatment; this finding may 
explain, at least in part, the higher mean total score at 
Mini-ICF-APP observed in this study. With regard to 
concurrent validity, a high negative correlation was found 
between mean total score at Mini-ICF-APP (where lower 
scores indicate better functioning) and mean total score 
at PSP (where lower scores indicate worse functioning); 
moreover, a significant negative correlation was found 
between all Mini-ICF-APP items, with the exception of 
“mobility”, and mean total score at PSP. When taking into 
account correlations between each item of Mini-ICF-
APP and PSP domains, we found that four items of the 
former (“adherence to regulations”, “structuring of tasks”, 
“flexibility”, and “spontaneous activity”) were signifi-
cantly correlated with three PSP domains (“socially useful 
activities”, “personal and social relations” and “self-care”). 
Furthermore, eight items of Mini-ICF-APP (“flexibil-
ity”, “competency”, “endurance”, “assertiveness”, “contact 
with others”, “group integration”, “intimate relationships” 
“spontaneous activities” and “judgement”) significantly 
correlated with two PSP domains (“socially useful activi-
ties” and “personal and social relations”). The only item 
Table 8 Mini-ICF-APP mean scores ± SD according to clinical remission status
Item Remitted (N = 40) Non remitted (N = 34) Cohen’s d t value (df) p value
Adherence to regulations 0.70 (0.99) 1.12 (1.12) −0.379 −1.682 (66.5) 0.094
Structuring of tasks 1.15 (1.23) 2.06 (1.04) −0.798 −3.438 (72) 0.001
Flexibility 1.67 (1.22) 2.35 (0.92) −0.629 −2.651 (72) 0.010
Competency 1.75 (1.22) 2.32 (1.09) −0.492 −2.188 (72.00) 0.038
Endurance 1.57 (1.30) 2.26 (1.31) −0.528 −2.266 (69.89) 0.027
Assertiveness 1.32 (1.16) 1.71 (1.24) −0.324 −1.352 (68.34) 0.181
Contact with others 1.32 (1.18) 1.97 (1.19) −0.506 −2.327 (69.90) 0.023
Group integration 1.22 (1.25) 2.09 (1.14) −0.727 −3.107 (71.64) 0.003
Intimate relations 1.50 (1.21) 2.35 (1.12) −0.729 −3.127 (72) 0.003
Spontaneous activity 1.37 (1.17) 2.26 (0.99) −0.821 −3.537 (72) 0.001
Self-care 0.55 (0.68) 0.88 (0.98) −0.391 −1.671 (57.36) 0.10
Mobility 0.82 (1.15) 0.88 (1.17) −0.050 −0.211 (69.40) 0.83
Judgement 1.50 (1.15) 2.03 (1.03) −0.485 −2.085 (71.82) 0.041
Total score 16.47 (11.84) 24.29 (10.33) −0.703 −3.033 (71.94) 0.003
Table 9 Mini-ICF-APP mean scores ± SD according to functional remission status
Item Remitted (N = 22) Non remitted (N = 52) Cohen’s d t value (df) p value
Adherence to regulations 0.54 (0.80) 1.04 (1.13) −0.510 −2.122 (55.5) 0.038
Structuring of tasks 1.18 (1.33) 1.73 (1.16) −0.440 −1.683 (35.06) 0.101
Flexibility 1.54 (1.22) 2.17 (1.06) −0.551 −2.095 (35.03) 0.043
Competency 1.64 (1.40) 2.17 (1.07) −0.425 −1.608 (32.08) 0.118
Endurance 1.18 (1.29) 2.19 (1.25) −0.795 −3.096 (38.42) 0.004
Assertiveness 1.23 (1.23) 1.61 (1.19) −0.314 −1.251 (38.41) 0.218
Contact with others 1.23 (1.30) 1.79 (1.16) −0.454 −1.744 (35.71) 0.090
Group integration 1.14 (1.21) 1.83 (1.25) −0.560 −2.227 (40.85) 0.032
Intimate relations 1.23 (1.23) 2.17 (1.15) −0.789 −3.078 (37.25) 0.004
Spontaneous activity 1.32 (1.29) 1.98 (1.07) −0.556 −2.122 (34.02) 0.041
Self-care 0.41 (0.66) 0.83 (0.87) −0.543 −2.232 (51.79) 0.030
Mobility 0.82 (1.33) 0.86 (1.08) −0.030 −0.147 (33.36) 0.884
Judgement 1.41 (1.18) 1.88 (1.08) −0.415 −1.623 (36.54) 0.113
Total score 14.86 (12.02) 22.27 (11.05) −0.641 −2.479 (36.76) 0.018
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of Mini-ICF-APP that failed to show a significant cor-
relation with any PSP domain was “Mobility”, while the 
PSP domain that failed to correlate with any Mini-ICF-
APP item was “aggressive and disturbing behaviour”. 
Taken together, these findings demonstrate a fairly good 
concurrent validity with PSP, as previously shown in the 
validation study for both the Italian [13] and the English 
versions [12] of the instrument. It should be pointed out 
that similar results were also obtained by Schaub et  al. 
[38], who found a highly significant correlation between 
Mini-ICF-APP total score and PSP total score, in a study 
performed to validate the German version of the instru-
ment in chronic schizophrenic patients.
Although schizophrenic symptomatology and function-
ing are only partially inter-related, being seen as semi-
independent outcome measures [39], and despite the 
fact that clinical remission does not always imply func-
tional remission [33, 35], significant positive correlations 
between symptom severity and impaired functioning 
are generally reported in the literature [1]. In our study, 
Mini-ICF-APP total scores were significantly correlated 
with overall scores of both CGI-SCHs and PANSS, a 
finding indicating a clear relationship between severity 
of symptomatology and degree of severity of functional 
deficits measured by Mini-ICF-APP, while no correla-
tions were observed with ratings of positive symptoms 
evaluated by both CGI-SCHs and PANSS. Lastly, depres-
sive symptomatology and cognitive impairment evaluated 
by CGI-SCHs, and general psychopathology evaluated 
by means of PANSS, were all significantly and positively 
correlated with Mini-ICF-APP total scores. These results 
are largely in agreement with those of Balestrieri et  al. 
[13], who found a highly significant correlation between 
Mini-ICF-APP total score and both CGI-severity score 
and BPRS global score in their subsample of schizophren-
ics. Moreover, using BPRS, the same authors found a sig-
nificant correlation between Mini-ICF-APP total score 
and several “positive” symptoms (“grandiosity”, “hostil-
ity”, “suspiciousness”, “hallucinations”, “unusual thought 
content”), “mood” symptoms (“guilt”, “elated mood”, 
“excitement”), and “negative symptoms” (“emotional with-
drawal”, “uncooperativeness”). The partial incongruence 
between the results obtained in our study and those of the 
study mentioned above [13], particularly the association 
between positive symptoms and functioning, may at least 
in part be explained by the previously cited difference in 
severity of clinical status between patient samples inves-
tigated in the two studies, as the study conducted by our 
group comprised a fairly stable sample of patients with 
less severe chronic illness. It should be taken into account 
that contrasting data are present in literature relating to 
the role of positive symptoms in disability, while a posi-
tive correlation of functioning with negative and depres-
sive symptoms is generally reported [5, 38]. In addition 
to the correlation observed between severity of cognitive 
deficits clinically measured using CGI-SCHs cognitive 
scale and severity of functioning measured by Mini-ICF-
APP, we also detected significant correlations with the 
MMSE and with three out of six BACS domains; this find-
ing was not unexpected, particularly in view of the well 
established relationship between cognitive and real-world 
functioning deficits in schizophrenic patients [40]. To 
establish construct validity, differences in Mini-ICF-APP 
scores were evaluated, resulting in the expected outcome 
of significant differences between remitted and recovered 
patients. Indeed, both clinically and functionally remitted 
Table 10 Mini-ICF-APP mean scores ± SD according to recovery status
Item Recovered (N = 20) Non recovered (N = 54) Cohen’s d t value (df) p value
Adherence to regulations 0.55 (0.82) 1.02 (1.12) −0.478 −1.954 (46.24) 0.057
Structuring of tasks 1.15 (1.38) 1.72 (1.14) −0.450 −1.650 (29.04) 0.110
Flexibility 1.50 (1.23) 2.16 (1.06) −0.574 −2.139 (29.96) 0.041
Competency 1.65 (1.46) 2.15 (1.07) −0.390 −1.604 (72) 0.113
Endurance 1.30 (1.30) 2.11 (1.29) −0.625 −2.382 (33.92) 0.023
Assertiveness 1.30 (1.26) 1.57 (1.19) −0.220 −0.843 (32.37) 0.406
Contact with others 1.30 (1.34) 1.74 (1.17) −0.349 −1.298 (30.32) 0.204
Group integration 1.10 (1.25) 1.81 (1.23) −0.572 −2.191 (33.46) 0.036
Intimate relations 1.30 (1.26) 2.11 (1.18) −0.663 −2.502 (32.03) 0.018
Spontaneous activity 1.30 (1.34) 1.96 (1.06) −0.546 −1.990 (28.32) 0.056
Self-care 0.45 (0.68) 0.79 (0.87) −0.435 −1.781 (43.25) 0.082
Mobility 0.90 (1.37) 0.83 (1.07) 0.056 −0.196 (28.13) 0.846
Judgement 1.40 (1.23) 1.87 (1.06) −0.409 −1.512 (30.16) 0.141
Total score 15.20 (12.46) 21.87 (11.08) −0.565 −2.105 (30.82) 0.044
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patients displayed a significantly higher Mini-ICF-APP 
total score compared to unremitted subjects, thus indicat-
ing consistently improved functioning; a similar finding 
was revealed for “recovered” patients, i.e. patients charac-
terized by both clinical and functional remission. More-
over, on analysis, differences in mean scores obtained at 
each of the thirteen Mini-ICF-APP items provided con-
firmation of the above findings for a consistent number 
of items, highlighting better results among remitted and 
recovered patients for the majority of functioning aspects 
covered by Mini-ICF-APP. Finally, as expected we found 
no consistent correlations between Mini-ICF-APP and 
SWN-S, a result in favour of a fairly good discriminant 
validity of the instrument.
Before drawing conclusions, several limitations of the 
present study should be taken into account. In particu-
lar, the rather limited size of the study sample, and the 
prevalent focus on chronic outpatients limit the validity 
of our findings to the sole patients studied. Addition-
ally, sample heterogeneity should be taken into account, 
due to inclusion in the study of patients affected by both 
schizophrenia and schizoaffective disorders. However, it 
should be underlined that in our cohort no differences in 
sociodemographic and clinical parameters were detected 
between the two diagnostic subsamples. However, even 
in the light of these limitations, the evidence obtained 
would seem to be of interest for clinicians.
Conclusions
Results obtained in this study show that the Mini-ICF-
APP is a valid measure of functioning for use in chronic 
patients affected by schizophrenia and schizoaffec-
tive disorders. Moreover, the tool holds characteristics 
which are not available in other instruments [13], which 
specifically enable the measurement of “capacities”, and 
addresses aspects of functioning of particular relevance 
to the working environment [12]. Therefore, in our opin-
ion, Mini-ICF-APP should be given due recognition and 
added to the scenario of existing instruments intended 
for use in evaluating functioning in the mentally ill. 
Moreover, the user-friendly and streamlined application 
of the instrument is particularly suited for use in a rou-
tine psychiatric setting.
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